Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22194461 | 0.72 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL22194460 | 0.72 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL10034876 | 0.69 | ABCB1 (0.37) | MAOAMAOBGUSBMEN1KMT2A | |
| SCHEMBL28394596 | 0.66 | PIM1 (0.33) | MAOAMAOBMEN1KMT2A | |
| SCHEMBL14276365 | 0.65 | MAOA (0.32) | MAOAMAOBGUSB | |
| SCHEMBL29453972 | 0.64 | ESR1 (0.36) | MAOAMAOBMEN1KMT2A | |
| SCHEMBL17051496 | 0.64 | MAOA (0.46) | MAOAMAOBGUSBMEN1KMT2A | |
| SCHEMBL21500047 | 0.63 | NR3C1 (0.34) | MAOAMAOBGUSBMEN1KMT2A | |
| SCHEMBL29194950 | 0.63 | PIM1 (0.34) | SGMS2MAOAMAOB | |
| SCHEMBL23604441 | 0.63 | MAOA (0.37) | MAOAMAOBGUSBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442808-B2 | e.g. 3-(indan-1-yloxy)-8-(oxazolidin-2,4-dion-5-yl)-5,6,7,8-tetrahydroquinoline; with other active ingredients; agonists of G-protein coupled receptor 40 (GPR40); antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity, hyperlipemia | MERCK & CO., INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265332-A1 | Antidiabetic bicyclic compounds | GPR119, GPR65, FFAR4 | SGMS2 435/4885MAOA 4143/4885MAOB 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.